Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01674478 · ClinicalTrials.gov registry record · Phase 2
Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies
A Phase 2 study, sponsored by Wake Forest University.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01674478 is a Phase 2 study that has completed, run by Wake Forest University. The registered enrollment target is 18 participants.
The verdict
NCT01674478, a Phase 2 study, has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
Necrotizing enterocolitis (NEC) and spontaneous intestinal perforation (SIP) are common devastating gastrointestinal diseases in premature infants. These infants often need surgical intervention to remove the dead bowel and create temporary enterostomies, resulting in short bowel syndrome (SBS), a malabsorption state due to insufficient bowel length or dysfunction to digest and absorb nutrients adequately. These infants are often nourished primarily with parental nutrition (PN) which can lead to many complications including PN-associated liver disease. However, with enteral feeding, the remaining bowel can adapt somewhat to the shortened state, reducing the need for PN. Enteral fats appear to be the most trophic macronutrients with the long chain polyunsaturated fatty acids (LCPUFA) being the most beneficial in promoting bowel adaptation. Fish oil (FO), a main source of n-3 LCPUFA, has been shown to promote bowel adaptation. Microlipid (ML) primarily contains n-6 PUFA and has been found to decrease ostomy output and increase weight gain in some SBS infants. WThe investigators will soon have completed a randomized clinical trial (EMLFO trial) (WFUHS IRB00011501, NCT01306838) entitled "Early Supplementation of Enteral Lipid with Combination of Microlipid and Fish Oil in Infants with Enterostomies". The preliminary data suggest that (a) by supplementing enteral ML/FO, we were able to decrease the use of IL; (b) premature infants in the treatment group who received ML/FO achieved higher enteral calorie (% of total calorie) intake before reanastomosis and better weight gain (g/day) after reanastomosis than those who received routine care in control group; and (c) the direct bilirubin level before reanastomosis tended to be lower in the treatment group than the control group although the difference was not statistically significant. Because the intervention consisted of both an increase in enteral fat intake as well as a specific type of fat intake (i.e. FO), it is uncl
Interventions
- DIETARY_SUPPLEMENT Microlipid with fish oil
- DIETARY_SUPPLEMENT Microlipid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-03-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01674478
The ClinicalTrials.gov registry entry for NCT01674478 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Microlipid with fish oil is the first listed.
NCT01674478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01674478 about?
NCT01674478 is a clinical study titled "Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies". Necrotizing enterocolitis (NEC) and spontaneous intestinal perforation (SIP) are common devastating gastrointestinal diseases in premature infants. These infants often need surgical intervention to remove the dead bowel and create temporary enterostomies, resulting in short bowel syndrome (SBS), a m...
What is the current status of trial NCT01674478?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2012-10. Estimated completion is 2015-03-17.
What interventions are being tested in trial NCT01674478?
The interventions under investigation include: Microlipid with fish oil (DIETARY_SUPPLEMENT), Microlipid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01674478?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.